Skip to main content
Erschienen in: Endocrine 2/2019

25.01.2019 | Original Article

68Ga-DOTANOC and 18F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers

verfasst von: Pedro Souteiro, Patrícia Gouveia, Gonçalo Ferreira, Sandra Belo, Cláudia Costa, Davide Carvalho, Hugo Duarte, Inês Lucena Sampaio

Erschienen in: Endocrine | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

Metastatic disease is common in medullary thyroid carcinoma (MTC) and it is usually detected by raising calcitonin and carcinoembryonic antigen (CEA) levels. Nuclear medicine imaging has an important role in lesion identification/characterisation. We aim to compare 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT performance and to explore the correlations between tumoral markers and functional imaging.

Methods

This a retrospective cross-sectional study including 13 patients with MTC and high calcitonin/CEA levels that underwent both 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT.

Results

68Ga-DOTANOC PET/CT identified MTC metastases in 2twopatients that were 18F-FDG-negative (sensitivity of 69.2% vs. 53.9%, respectively). 68Ga-DOTANOC PET/CT also detected a higher number of lesions than 18F-FDG PET/CT in seven patients, with only one patient showing the opposite pattern. Both differences lacked statistical significance (p = 0.50 and p = 0.86, respectively) but 68Ga-DOTANOC PET/CT better performance allowed changes in patients’ management. 68Ga-positive/18F-FDG-negative patients were the ones with the lowest calcitonin doubling time and presented a CEA doubling time >24 months, while the patient with more 18F-FDG-positive lesions was the one with the highest CEA/calcitonin ratio. The number of lesions found in 68Ga-DOTANOC PET/CT were correlated with calcitonin levels (r = 0.73; p < 0.01) but not with CEA ones (r = 0.42; p = 0.15). The number of 18F-FDG hypermetabolic focus were correlated with CEA levels (r = 0.60; p < 0.05) but not with calcitonin (r = 0.48; p = 0.09).

Conclusions

This is the first study to describe a positive correlation between 68Ga-positive lesions and calcitonin levels and between 18F-FDG-positivity and CEA levels. Tumoral markers pattern in metastatic MTC could help clinicians to decide which exam to perform first.
Literatur
1.
Zurück zum Zitat S.A. Wells Jr., S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567–610 (2015)CrossRefPubMedPubMedCentral S.A. Wells Jr., S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567–610 (2015)CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat F. Pacini, M.G. Castagna, C. Cipri, M. Schlumberger, Medullary thyroid carcinoma. Clin. Oncol. (R. Coll. Radiol.) 22, 475–485 (2010)CrossRef F. Pacini, M.G. Castagna, C. Cipri, M. Schlumberger, Medullary thyroid carcinoma. Clin. Oncol. (R. Coll. Radiol.) 22, 475–485 (2010)CrossRef
3.
Zurück zum Zitat J. Schmidt Jensen, C. Gronhoj, C. Mirian, D.H. Jensen, J. Friborg, C.H. Hahn et al. Incidence and survival of thyroid cancer in children, adolescents, and young adults in Denmark: A Nationwide Study from 1980 to 2014. Thyroid 28, 1128–1133 (2018)CrossRefPubMed J. Schmidt Jensen, C. Gronhoj, C. Mirian, D.H. Jensen, J. Friborg, C.H. Hahn et al. Incidence and survival of thyroid cancer in children, adolescents, and young adults in Denmark: A Nationwide Study from 1980 to 2014. Thyroid 28, 1128–1133 (2018)CrossRefPubMed
4.
Zurück zum Zitat F. Torresan, E. Cavedon, C. Mian, M. Iacobone, Long-term outcome after surgery for medullary thyroid carcinoma: A single-center experience. World J. Surg. 42, 367–375 (2018)CrossRefPubMed F. Torresan, E. Cavedon, C. Mian, M. Iacobone, Long-term outcome after surgery for medullary thyroid carcinoma: A single-center experience. World J. Surg. 42, 367–375 (2018)CrossRefPubMed
5.
Zurück zum Zitat A. Machens, J. Ukkat, S. Hauptmann, H. Dralle, Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch. Surg. (Chic., Ill: 1960) 142, 289–293 (2007). (discussion 294) A. Machens, J. Ukkat, S. Hauptmann, H. Dralle, Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch. Surg. (Chic., Ill: 1960) 142, 289–293 (2007). (discussion 294)
6.
Zurück zum Zitat K. Saltiki, G. Rentziou, K. Stamatelopoulos, G. Georgiopoulos, C. Stavrianos, E. Lambrinoudaki et al. Small medullary thyroid carcinoma: post-operative calcitonin rather than tumour size predicts disease persistence and progression. Eur. J. Endocrinol. 171, 117–126 (2014)CrossRefPubMed K. Saltiki, G. Rentziou, K. Stamatelopoulos, G. Georgiopoulos, C. Stavrianos, E. Lambrinoudaki et al. Small medullary thyroid carcinoma: post-operative calcitonin rather than tumour size predicts disease persistence and progression. Eur. J. Endocrinol. 171, 117–126 (2014)CrossRefPubMed
7.
Zurück zum Zitat A. Laure Giraudet, A. Al Ghulzan, A. Auperin, S. Leboulleux, A. Chehboun, F. Troalen et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur. J. Endocrinol. 158, 239–246 (2008)CrossRefPubMed A. Laure Giraudet, A. Al Ghulzan, A. Auperin, S. Leboulleux, A. Chehboun, F. Troalen et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur. J. Endocrinol. 158, 239–246 (2008)CrossRefPubMed
8.
Zurück zum Zitat M.F. Bozkurt, I. Virgolini, S. Balogova, M. Beheshti, D. Rubello, C. Decristoforo et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur. J. Nucl. Med. Mol. Imaging 44, 1588–1601 (2017)CrossRefPubMed M.F. Bozkurt, I. Virgolini, S. Balogova, M. Beheshti, D. Rubello, C. Decristoforo et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur. J. Nucl. Med. Mol. Imaging 44, 1588–1601 (2017)CrossRefPubMed
9.
Zurück zum Zitat G. Treglia, P. Castaldi, M.F. Villani, G. Perotti, C. de Waure, A. Filice et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 39, 569–580 (2012)CrossRefPubMed G. Treglia, P. Castaldi, M.F. Villani, G. Perotti, C. de Waure, A. Filice et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 39, 569–580 (2012)CrossRefPubMed
10.
Zurück zum Zitat B.G. Conry, N.D. Papathanasiou, V. Prakash, I. Kayani, M. Caplin, S. Mahmood et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 37, 49–57 (2010)CrossRefPubMed B.G. Conry, N.D. Papathanasiou, V. Prakash, I. Kayani, M. Caplin, S. Mahmood et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 37, 49–57 (2010)CrossRefPubMed
11.
Zurück zum Zitat E. Mato, X. Matias-Guiu, A. Chico, S.M. Webb, R. Cabezas, L. Berna et al. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 83, 2417–2420 (1998)PubMed E. Mato, X. Matias-Guiu, A. Chico, S.M. Webb, R. Cabezas, L. Berna et al. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 83, 2417–2420 (1998)PubMed
12.
Zurück zum Zitat M.O. Oksuz, L. Winter, C. Pfannenberg, G. Reischl, K. Mussig, R. Bares et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn. Interv. Imaging 95, 289–300 (2014)CrossRefPubMed M.O. Oksuz, L. Winter, C. Pfannenberg, G. Reischl, K. Mussig, R. Bares et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn. Interv. Imaging 95, 289–300 (2014)CrossRefPubMed
13.
Zurück zum Zitat E. Hindié, The NETPET Score: Combining FDG and somatostatin receptor imaging for optimal management of patients with metastatic well-differentiated neuroendocrine tumors. Theranostics 7, 1159–1163 (2017)CrossRefPubMedPubMedCentral E. Hindié, The NETPET Score: Combining FDG and somatostatin receptor imaging for optimal management of patients with metastatic well-differentiated neuroendocrine tumors. Theranostics 7, 1159–1163 (2017)CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat G. Treglia, V. Rufini, M. Salvatori, A. Giordano, L. Giovanella, PET imaging in Recurrent Medullary Thyroid Carcinoma. Int. J. Mol. Imaging 2012, 324686 (2012)PubMedPubMedCentral G. Treglia, V. Rufini, M. Salvatori, A. Giordano, L. Giovanella, PET imaging in Recurrent Medullary Thyroid Carcinoma. Int. J. Mol. Imaging 2012, 324686 (2012)PubMedPubMedCentral
15.
Zurück zum Zitat A. Miyauchi, T. Onishi, S. Morimoto, S. Takai, F. Matsuzuka, K. Kuma et al. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann. Surg. 199, 461–466 (1984)CrossRefPubMedPubMedCentral A. Miyauchi, T. Onishi, S. Morimoto, S. Takai, F. Matsuzuka, K. Kuma et al. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann. Surg. 199, 461–466 (1984)CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat R.M. Tuttle, B. Haugen, N.D. Perrier, Updated American Joint Committee on cancer/tumor-node-metastasis staging system for differentiated and anaplasticthyroid cancer (eighth edition): What changed and why? Thyroid 27, 751–756 (2017)CrossRefPubMedPubMedCentral R.M. Tuttle, B. Haugen, N.D. Perrier, Updated American Joint Committee on cancer/tumor-node-metastasis staging system for differentiated and anaplasticthyroid cancer (eighth edition): What changed and why? Thyroid 27, 751–756 (2017)CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat N. Naswa, P. Sharma, S. Suman Kc, S. Lata, R. Kumar, A. Malhotra et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Nucl. Med. Commun. 33, 766–774 (2012)CrossRefPubMed N. Naswa, P. Sharma, S. Suman Kc, S. Lata, R. Kumar, A. Malhotra et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Nucl. Med. Commun. 33, 766–774 (2012)CrossRefPubMed
18.
Zurück zum Zitat Z.G. Ozkan, S. Kuyumcu, A.K. Uzum, M.F. Gecer, S. Ozel, F. Aral et al. Comparison of (6)(8)Ga-DOTATATE PET-CT, (1)(8)F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl. Med. Commun. 36, 242–250 (2015)CrossRefPubMed Z.G. Ozkan, S. Kuyumcu, A.K. Uzum, M.F. Gecer, S. Ozel, F. Aral et al. Comparison of (6)(8)Ga-DOTATATE PET-CT, (1)(8)F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl. Med. Commun. 36, 242–250 (2015)CrossRefPubMed
20.
Zurück zum Zitat A. Mojtahedi, S. Thamake, I. Tworowska, D. Ranganathan, E.S. Delpassand, The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. Am. J. Nucl. Med. Mol. Imaging 4, 426–434 (2014)PubMedPubMedCentral A. Mojtahedi, S. Thamake, I. Tworowska, D. Ranganathan, E.S. Delpassand, The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. Am. J. Nucl. Med. Mol. Imaging 4, 426–434 (2014)PubMedPubMedCentral
21.
Zurück zum Zitat M. Papotti, U. Kumar, M. Volante, C. Pecchioni, Y.C. Patel, Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin. Endocrinol. (Oxf.). 54, 641–649 (2001)CrossRefPubMed M. Papotti, U. Kumar, M. Volante, C. Pecchioni, Y.C. Patel, Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin. Endocrinol. (Oxf.). 54, 641–649 (2001)CrossRefPubMed
22.
Zurück zum Zitat F. Vaisman, P.H. Rosado de Castro, F.P. Lopes, D.B. Kendler, C.H. Pessoa, D.A. Bulzico et al. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer? Clin. Nucl. Med. 40, 123–127 (2015)CrossRefPubMed F. Vaisman, P.H. Rosado de Castro, F.P. Lopes, D.B. Kendler, C.H. Pessoa, D.A. Bulzico et al. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer? Clin. Nucl. Med. 40, 123–127 (2015)CrossRefPubMed
23.
Zurück zum Zitat F. Iten, B. Muller, C. Schindler, C. Rochlitz, D. Oertli, H.R. Macke et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin. Cancer Res. 13, 6696–6702 (2007)CrossRefPubMed F. Iten, B. Muller, C. Schindler, C. Rochlitz, D. Oertli, H.R. Macke et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin. Cancer Res. 13, 6696–6702 (2007)CrossRefPubMed
24.
Zurück zum Zitat B. Nilica, D. Waitz, V. Stevanovic, C. Uprimny, D. Kendler, S. Buxbaum et al. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur. J. Nucl. Med. Mol. Imaging 43, 1585–1592 (2016)CrossRefPubMedPubMedCentral B. Nilica, D. Waitz, V. Stevanovic, C. Uprimny, D. Kendler, S. Buxbaum et al. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur. J. Nucl. Med. Mol. Imaging 43, 1585–1592 (2016)CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat J.A. Meijer, S. le Cessie, W.B. van den Hout, J. Kievit, J.W. Schoones, J.A. Romijn et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin. Endocrinol. (Oxf.). 72, 534–542 (2010)CrossRefPubMed J.A. Meijer, S. le Cessie, W.B. van den Hout, J. Kievit, J.W. Schoones, J.A. Romijn et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin. Endocrinol. (Oxf.). 72, 534–542 (2010)CrossRefPubMed
26.
Zurück zum Zitat H.H. Verbeek, J.T. Plukker, K.P. Koopmans, J.W. de Groot, R.M. Hofstra, A.C. Muller Kobold et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J. Nucl. Med. 53, 1863–1871 (2012)CrossRefPubMed H.H. Verbeek, J.T. Plukker, K.P. Koopmans, J.W. de Groot, R.M. Hofstra, A.C. Muller Kobold et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J. Nucl. Med. 53, 1863–1871 (2012)CrossRefPubMed
27.
Zurück zum Zitat T.V. Bogsrud, D. Karantanis, M.A. Nathan, B.P. Mullan, G.A. Wiseman, J.L. Kasperbauer et al. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol. Imaging Biol.: MIB 12, 547–553 (2010)CrossRefPubMed T.V. Bogsrud, D. Karantanis, M.A. Nathan, B.P. Mullan, G.A. Wiseman, J.L. Kasperbauer et al. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol. Imaging Biol.: MIB 12, 547–553 (2010)CrossRefPubMed
28.
Zurück zum Zitat A.L. Giraudet, D. Vanel, S. Leboulleux, A. Auperin, C. Dromain, L. Chami et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 92, 4185–4190 (2007)CrossRefPubMed A.L. Giraudet, D. Vanel, S. Leboulleux, A. Auperin, C. Dromain, L. Chami et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 92, 4185–4190 (2007)CrossRefPubMed
29.
Zurück zum Zitat L.Y.I. Yamaga, M.L. Cunha, G.C. Campos Neto, M.R.T. Garcia, J.H. Yang, C.P. Camacho et al. 68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111)In-octreotide SPECT/CT and conventional imaging. Eur. J. Nucl. Med. Mol. Imaging 44, 1695–1701 (2017)CrossRefPubMed L.Y.I. Yamaga, M.L. Cunha, G.C. Campos Neto, M.R.T. Garcia, J.H. Yang, C.P. Camacho et al. 68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111)In-octreotide SPECT/CT and conventional imaging. Eur. J. Nucl. Med. Mol. Imaging 44, 1695–1701 (2017)CrossRefPubMed
30.
Zurück zum Zitat A.R. Romero-Lluch, J.I. Cuenca-Cuenca, R. Guerrero-Vazquez, A.J. Martinez-Ortega, J.L. Tirado-Hospital, I. Borrego-Dorado et al. Diagnostic utility of PET/CT with (18)F-DOPA and (18)F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur. J. Nucl. Med. Mol. Imaging 44, 2004–2013 (2017)CrossRefPubMed A.R. Romero-Lluch, J.I. Cuenca-Cuenca, R. Guerrero-Vazquez, A.J. Martinez-Ortega, J.L. Tirado-Hospital, I. Borrego-Dorado et al. Diagnostic utility of PET/CT with (18)F-DOPA and (18)F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur. J. Nucl. Med. Mol. Imaging 44, 2004–2013 (2017)CrossRefPubMed
Metadaten
Titel
68Ga-DOTANOC and 18F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers
verfasst von
Pedro Souteiro
Patrícia Gouveia
Gonçalo Ferreira
Sandra Belo
Cláudia Costa
Davide Carvalho
Hugo Duarte
Inês Lucena Sampaio
Publikationsdatum
25.01.2019
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-01846-8

Weitere Artikel der Ausgabe 2/2019

Endocrine 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.